Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ST14 | Q9Y5Y6 | 3/20 | 0.55 |
| ▸ | MAOB | P27338 | 8/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | LOX | P28300 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 3/20 | 0.43 |
| ▸ | CDK8 | P49336 | 2/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14656344 | 0.84 | KIF11 (0.51) | HTR2ASLC6A4KCNH2ARCDK8 | |
| SCHEMBL875395 | 0.83 | IDO1 (0.54) | ST14MAOBLOXLOXL2AR | |
| SCHEMBL1283223 | 0.81 | ALDH1A1 (0.50) | MAOBHTR2ASLC6A4KCNH2AR | |
| SCHEMBL4369759 | 0.81 | ST14 (0.64) | ST14MAOBLOXL2 | |
| SCHEMBL41769 | 0.81 | PTPN7 (0.45) | MAOBLOXLOXL2AR | |
| SCHEMBL4368153 | 0.78 | CDK8 (0.47) | HTR2ASLC6A4KCNH2ARCDK8 | |
| SCHEMBL1282625 | 0.77 | AR (0.49) | HTR2ASLC6A4KCNH2ARCDK8 | |
| SCHEMBL923443 | 0.77 | ST14 (0.58) | ST14MAOBHTR2ASLC6A4KCNH2 | |
| SCHEMBL4380034 | 0.77 | ST14 (0.58) | ST14MAOBHTR2ASLC6A4KCNH2 | |
| SCHEMBL922221 | 0.75 | MAOB (0.69) | ST14MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009117421-A2 | HETEROCYCLIC MODULATORS OF GPR119 FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-09-24 | — | — | WO | disclosed |